Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.70 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.70 |
| ▸ | GAK | O14976 | 2/20 | 0.70 |
| ▸ | ABL1 | P00519 | 2/20 | 0.70 |
| ▸ | LCK | P06239 | 2/20 | 0.70 |
| ▸ | MET | P08581 | 2/20 | 0.70 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.70 |
| ▸ | BLK | P51451 | 2/20 | 0.70 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.70 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.70 |
| ▸ | EPHA6 | Q9UF33 | 2/20 | 0.70 |
| ▸ | CIT | O14578 | 1/20 | 0.70 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.70 |
| ▸ | STK10 | O94804 | 1/20 | 0.70 |
| ▸ | LYN | P07948 | 1/20 | 0.70 |
| ▸ | RET | P07949 | 1/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623740 | 1.00 | EGFR (0.72) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL209451 | 1.00 | EGFR (0.72) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1190638 | 0.99 | EGFR (0.72) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1190639 | 0.99 | EGFR (0.72) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1191816 | 0.94 | EGFR (0.78) | EGFRERBB2ERBB4GAKABL1 | |
| Afatinib SCHEMBL1199626 | 0.93 | EGFR (0.84) | EGFRERBB2ERBB4GAKABL1 | |
| Afatinib SCHEMBL20603858 | 0.93 | EGFR (0.84) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1191557 | 0.93 | EGFR (0.71) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1191559 | 0.93 | EGFR (0.71) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL1191161 | 0.92 | EGFR (0.84) | EGFRERBB2ERBB4GAKABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 742 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016025641-A1 | COMBINATIONS OF AN ERK INHIBITOR AND AN EGFR INHIBITOR AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | claimed |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG. (DE) | 2010-12-09 | — | — | US | claimed |
| US-20100144639-A1 | USE OF INHIBITORS OF THE EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / PROSTATIC HYPERTROPHY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | claimed |
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | claimed |
| EP-1478398-B1 | NEW MEDICINAL COMPOSITIONS ON THE BASIS OF ANTICHOLINERGIC AGENTS AND EGFR KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-05-06 | — | — | EP | claimed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | claimed |
| EP-1901776-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | Boehringer Ingelheim International GmbH (DE) | 2008-03-26 | — | — | EP | claimed |
| JP-2007517819-A | — | — | 2007-07-05 | — | — | JP | claimed |
| US-20070099918-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | claimed |
| EP-1478398-A1 | NEW MEDICINAL COMPOSITIONS ON THE BASIS OF ANTICHOLINERGIC AGENTS AND EGFR KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-11-24 | — | — | EP | claimed |
| EP-1474149-A2 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-11-10 | — | — | EP | claimed |
| US-20040048887-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| WO-2004004775-A1 | NOVEL DRUG COMPOSITIONS BASED ON NOVEL ANTICHOLINERGICS AND INHIBITORS OF EGFR-KINASE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | claimed |
| WO-2003094921-A2 | UTILIZATION OF INHIBITORS OF EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)/PROSTATIC HYPERTROPHY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-20 | — | — | WO | claimed |
| US-20030158196-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-08-21 | — | — | US | claimed |
| WO-2003068264-A1 | NEW MEDICINAL COMPOSITIONS ON THE BASIS OF ANTICHOLINERGIC AGENTS AND EGFR KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-08-21 | — | — | WO | claimed |
| WO-2003066060-A2 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-08-14 | — | — | WO | claimed |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-08-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885ERBB4 3/4885 |
| US-20070099918-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy | BPHL, EGFR, ERBB3 | EGFR 2/4885ERBB2 4/4885ERBB4 6/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | EGFR 53/4885ERBB2 29/4885ERBB4 44/4885 |
| US-20100144639-A1 | USE OF INHIBITORS OF THE EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / PROSTATIC HYPERTROPHY | BPHL, EGFR, ERBB3 | EGFR 2/4885ERBB2 4/4885ERBB4 6/4885 |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | PDE4B, CHRM3, ADRA2C | EGFR 43/4885ERBB2 75/4885ERBB4 22/4885 |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885ERBB4 3/4885 |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BPHL, EGFR, ERBB3 | EGFR 2/4885ERBB2 4/4885ERBB4 6/4885 |
| US-20040048887-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | CHRM3, EGFR, ERBB2 | EGFR 2/4885ERBB2 3/4885ERBB4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.